The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

Diabetes Research and Clinical Practice

Volumn 95, Issue 1, 2012, Pages

  Maeda, Hajime ^a   Kubota, Akira ^a   Tanaka, Yasushi ^b   Terauchi, Yasuo ^c   Matsuba, Ikuro ^a  

^a Kanagawa Physicians Association   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

BMI; Dipeptidyl peptidase 4 (DPP 4) inhibitor; HbA1c; Sitagliptin

Indexed keywords

1,5 ANHYDROSORBITOL; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; RISK FACTOR; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; WEIGHT GAIN;

AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 84355162099     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.10.011     Document Type: Article

References (10)

1. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H. Efficiency and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:737-745. for Stein P for the Sitagliptin 035 Study Group.
2. Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P., et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010, 64:562-576. Sitagliptin Study 024 Group.
3. Reasner C., Olansky L., Seck T.L., Williams-Herman D.E., Chen M., Terranella L., et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:644-652.
4. Goldstein B.J., Johnson J., Feinglos M.N., Williams-Herman D.E., Lunceford J.K. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987. for the Sitagliptin 036 Study Group.
5. Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24:537-550.
6. Yoon K.H., Shockey G.R., Teng R., Golm G.T., Thakkar P.R., Meehan A.G., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 2011, 65:154-164.
7. Aoki K., Masuda K., Miyazaki T., Togashi Y., Terauchi Y. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 2010, 57:667-672.
8. Mistry G.C., Maes A.L., Lasseter K.C., Davies M.J., Gottesdiener K.M., Wagner J.A., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008, 48:592-598.
9. Esposito K., Cozzolino D., Bellastella G., Maiorino M.I., Chiodini P., Ceriello A., et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011, 13:594-603.
10. Nauck M.A., Vardarli I., Deacon C.F., Holst J.J., Meier J.J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 2011, 54:10-18.